Weight loss

Suggested

3 studies · 1 recommendation

Last updated: February 21, 2026

Suggested3 studies

Weight management improves prostate cancer outcomes and reduces treatment escalation risk

Three RCTs involving 897 participants consistently link weight loss to better prostate cancer outcomes. In a trial of 206 men with unfavorable-risk prostate cancer, overweight/obese men required salvage androgen suppression therapy significantly earlier than normal-weight men (median 3.7 vs. 6.9 years; HR 1.11 per BMI unit; P = 0.002), with a clear dose-response relationship (P < 0.001 for trend). An exercise-focused RCT of 50 men with localized prostate cancer achieved 2.0 kg mean body mass reduction (95% CI -2.9, -1.1) over 12 months, accompanied by clinically meaningful blood pressure improvements (systolic -13 mmHg, diastolic -8 mmHg) and 92% retention. A third trial of 641 overweight long-term cancer survivors demonstrated that sustained diet-exercise adherence significantly reduced BMI (β = -0.06, p < 0.05). Maintaining a healthy weight through combined dietary modification and regular exercise may delay disease progression and reduce the need for additional hormonal therapy.

Evidence

Exercise training as a novel primary treatment for localised prostate cancer: a multi-site randomised controlled phase II study

Authors: A Bandura, AK Eriksen, B Gardner, B Verplanken, C Bosco, C Renzi, FC Hamdy, G Godin, GA Borg, GJ Koelwyn, HH Kyu, HJ Tan, J Sim, L Bourke, LA Kaminsky, MR Law, R Horne, SM Eldridge, T Hvid, T Kroll, T Li, TJ Wilt, WC Willett, YL Le

Published: May 14, 2018

In this RCT of 50 men with low/intermediate-risk prostate cancer, the exercise training group (n=25) achieved a mean body mass reduction of 2.0 kg (95% CI -2.9, -1.1) over 12 months compared to usual care with physical activity advice (n=25). This weight loss accompanied reductions in systolic blood pressure of 13 mmHg (95% CI 7, 19) and diastolic blood pressure of 8 mmHg (95% CI 5, 12), indicating improved cardiovascular health indices. The 92% retention rate across both groups demonstrates the feasibility of sustained lifestyle modifications in this patient population.

View Source →

Diet and exercise intervention adherence and health-related outcomes among older long-term breast, prostate, and colorectal cancer survivors

Authors: Demark-Wahnefried, Wendy, Morey, Miriam C., Mosher, Catherine E., Rand, Kevin L., Snyder, Denise C., Winger, Joseph G.

Published: March 20, 2014

A randomized controlled trial tested a telephone and mailed print diet-exercise intervention among 641 older, overweight, long-term survivors of breast, prostate, and colorectal cancer over one year. Telephone session attendance showed a significant negative indirect relationship with BMI (β = -0.06, p < 0.05) mediated through intervention-period dietary and exercise behavior. The trial specifically enrolled overweight survivors and tracked behavioral changes at 14 time points, demonstrating that sustained adherence to both dietary and exercise components contributed to BMI reduction (NCT00303875).

View Source →

Evidence Suggesting That Obesity Prevention Measures May Improve Prostate Cancer Outcomes Using Data from a Prospective Randomized Trial

Authors: Chandra, Ravi A., Chen, Ming-Hui, D'Amico, Anthony V., Loffredo, Marian, Zhang, Danjie

Published: January 1, 2014

In a prospective randomized controlled trial of 206 men with unfavorable-risk prostate cancer treated with radiation therapy, 49 men who experienced PSA failure and received salvage androgen suppression therapy (sAST) were analyzed. Overweight/obese men required sAST significantly earlier than normal-weight men (median 3.7 vs. 6.9 years; adjusted hazard ratio 1.11 per unit BMI increase; 95% CI: 1.04–1.18; P = 0.002). A dose-response trend was observed: overweight/obese men with high-risk disease had the shortest time to sAST (2.3 years), followed by overweight/obese men with other-risk disease (4.6 years), and normal-weight men (6.9 years; P < 0.001 for trend).

View Source →